233 related articles for article (PubMed ID: 33017767)
1. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer stem cell vaccine with high expression of MUC1 serves as a novel prophylactic vaccine for colorectal cancer.
Guo M; Luo B; Pan M; Li M; Xu H; Zhao F; Dou J
Int Immunopharmacol; 2020 Nov; 88():106850. PubMed ID: 32777675
[TBL] [Abstract][Full Text] [Related]
3. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.
Guo M; Luo B; Pan M; Li M; Zhao F; Dou J
Int Immunopharmacol; 2020 Aug; 85():106631. PubMed ID: 32470879
[TBL] [Abstract][Full Text] [Related]
4. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Antitumor Efficacy of Cancer Stem Cell-Derived DRibble Vaccine on Colorectal Carcinoma.
Fu C; Tian G; Duan J; Liu K; Zhang C; Yan W; Wang Y
Int J Med Sci; 2021; 18(14):3249-3260. PubMed ID: 34400894
[TBL] [Abstract][Full Text] [Related]
6. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
7. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
8. Advances and perspectives of colorectal cancer stem cell vaccine.
Guo M; Dou J
Biomed Pharmacother; 2015 Dec; 76():107-20. PubMed ID: 26653557
[TBL] [Abstract][Full Text] [Related]
9. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
10. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
[TBL] [Abstract][Full Text] [Related]
12. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic tumor cell line-based vaccines: A good alternative to autologous and cancer stem cell vaccines in colorectal cancer.
Rafieenia F; Nikkhah E; Nourmohammadi F; Hosseini S; Abdollahi A; Sharifi N; Aliakbarian M; Forghani Fard MM; Gholamin M; Abbaszadegan MR
Iran J Basic Med Sci; 2021 Sep; 24(9):1231-1239. PubMed ID: 35083010
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine.
Hu B; Wang J; Guo Y; Chen T; Ni W; Yuan H; Zhang N; Xie F; Tai G
Int Immunopharmacol; 2016 Apr; 33():108-18. PubMed ID: 26896668
[TBL] [Abstract][Full Text] [Related]
15. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
17. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
18. Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.
Wu D; Yu X; Wang J; Hui X; Zhang Y; Cai Y; Ren M; Guo M; Zhao F; Dou J
J Immunol Res; 2019; 2019():9394615. PubMed ID: 31008116
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
Samuel J; Budzynski WA; Reddish MA; Ding L; Zimmermann GL; Krantz MJ; Koganty RR; Longenecker BM
Int J Cancer; 1998 Jan; 75(2):295-302. PubMed ID: 9462722
[TBL] [Abstract][Full Text] [Related]
20. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
Beatty PL; Narayanan S; Gariépy J; Ranganathan S; Finn OJ
Cancer Prev Res (Phila); 2010 Apr; 3(4):438-46. PubMed ID: 20332301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]